Luai Tabaza

I have been working on compiling this list for a while. These conferences and courses run every year and if they get cancelled given the current #COVID19 Pandemic, make sure you mark ur calendar for next year! Thank you ⁦@TCTMD_Yael⁩ & ⁦@TCTMD⁩ tctmd.com/news/program-every…

my.scai.org/discussion/membe… Thank you @SCAI for the feature

Grateful to be part of the faculty at @SVM_tweets Society for Vascular Medicine annual scientific sessions 2026, joining colleagues and leaders from around the world for hands-on technology workshops and great discussions on the complex management of pulmonary embolism and post PE syndromes. Always a pleasure to reconnect with old friends, meet new colleagues, and build new partnerships along the way.

Another one for the books. @VirtuaHealth IC team representing at @NCVHonline Philadelphia. @ButlerMd @VladLakhter @KinturSanghvi & Ibrahim moussa. Thank you @jcgeorgemd & @CraigMWalkerMD for a great meeting

We are reviewing our CTO PCI Billing. What is everyone doing when two operators are co-scrubbing? What codes/modifiers? #CTOoperators @SVRaoMD @DrBillLombardi @LAzzaliniMD @MichaelMegalyMD @djc795 @ziadalinyc @djkereiakes @AhmedAlOgaili @CtoEuro @CTOcomplication @karrowni @TaiKobayashiMD @JayMathewsMD @jaygirimd @JanzerSean @jcgeorgemd @DrTomWaggoner @KateKearney4 @esbrilakis @Allison_Dupont @RhianEDavies1 @TCTConference @ACCinTouch @YaserAlhamshari

Honored and deeply grateful to be recognized by @SCAI with the 30 in Their 30s award. This recognition reflects the mentors who guided me, the colleagues and friends who supported me, the fellows and trainees who continue to inspire me, and the patients who place their trust in us every day. This year has been especially meaningful with several personal and professional milestones that made me reflect even more on how much of this journey is shared. I am thankful to everyone who has been part of it and excited for what lies ahead. Congratulations to all of the other recipients. It is an honor to be recognized alongside such an inspiring group. @SCAI_Prez @RowanVirtuaSOM @VirtuaHealth @TCTMD @crfheart @SVM_tweets @JeffHealthEH @ACCmediacenter @American_Heart @ACCinTouch

His legacy will live on. May his soul rest in peace 🙏🏼

How the data emerging from #ACC26 will shape my thinking No single trial should redefine practice. Decisions remain anchored in the totality of evidence and the realities we face at the bedside. Axial mechanical support trials including PROTECT IV trial and CHIP-BCIS3 trial reinforce that high risk PCI is not a uniform entity. The signal is not universal. The opportunity lies in identifying the specific hemodynamic and anatomic subsets most likely to benefit from upfront support. LAAC data remind us that stroke risk in atrial fibrillation is not eliminated with closure. Contemporary anticoagulants carry a low risk of non major bleeding, a threshold that may fall further with emerging factor XI agents. Outcomes with WATCHMAN FLX appear favorable in selected lower risk patients, but potentially at the cost of higher stroke rates. Caution remains warranted before committing low bleeding risk patients to a permanent implant. IVUS in PCI continues to show incremental benefit, yet outcomes in high risk PCI appear similar with or without imaging. This is not unexpected. Operators who routinely use IVUS tend to internalize principles of sizing and optimization. The more relevant comparison may be between low and high IVUS utilization, and between early career operators with robust imaging training and those without. Catheter directed thrombolysis using EKOS system remains a sound option for intermediate risk pulmonary embolism when bleeding risk is acceptable, as supported by HI-PEITHO trial. While recent momentum has favored mechanical thrombectomy, it is reassuring to see continued support for CDT. In patients undergoing TAVI, routine PCI of stable coronary disease is not supported. A selective approach focused on lesions with clear prognostic relevance is more appropriate, though the field has yet to precisely define this threshold. AngioFFR is emerging as a practical method for ischemia assessment. Wire based physiology remains reliable and essential in specific settings. However, unlike wire based tools, angiography derived algorithms will continue to evolve with iterative learning, much like CT-FFR, and are likely to become increasingly central in routine practice. ORBITA-CTO trial adds an important perspective. CTO PCI offers meaningful improvement in symptoms and quality of life in carefully selected patients. There is a clear signal of benefit. For patients with refractory angina despite optimal therapy, CTO PCI should be viewed as a legitimate escalation strategy. @ACCinTouch @SCAI @TCTMD @RowanVirtuaSOM @SVM_tweets @TCTConference @TCT_ME_ @American_Heart @AHANewJersey @AHAPennsylvania @mmamas1973 @mirvatalasnag @djc795 @MichaelMegalyMD @GPAngioClub

Excellent data to support CTO PCI for symptom relief & quality of life improvement in select patients. This debunks the “sham effect” CTO PCI is often labeled with as it was directly compared to a sham procedure. Medical therapy is often inadequate & intolerable. Bottom line for those patients offer CTO PCI #ACC26 #CHIP #CTOPCI #SCAI @SCAI @ACCmediacenter @American_Heart @TCTMD @JACCJournals @ACCinTouch

Sharing some good news! I am honored to be selected into Cardiovascular Business Forty Under 40 Class of 2026 cardiovascularbusiness.com/t… @VirtuaHealth @RowanUniversity @CardioBusiness @SCAI @TCTMD @ACCinTouch @VMJ_SVM @JeffHealthNJ @BSCCardiology @MCWcardiology @IntMedatIowa @ACCmediacenter

People already ask AI for medical opinions. The general public should consult with their physician before implementing any treatment. Use the AI generated content to inform the discussion with the physician. Uploading medical data, even if de-identified is a privacy and security concern. You have no idea who can access/use that information. Once it’s out there, it’s out there. @elonmusk